ALKERMES | ALKS - Pasivo Circulante





Pasivo Circulante Cambio Fecha
AbbVie USD 43.29B 3.9B 2025-12
Acadia Pharmaceuticals USD 277.11M 79.47M 2025-12
ALKERMES USD 543.44M 69.08M 2025-12
Amgen USD 25.49B 3.7B 2025-12
Biogen USD 3.35B 59.4M 2025-12
BioMarin Pharmaceutical USD 759.03M 39.41M 2025-12
Bristol-Myers Squibb USD 28.14B 608M 2025-09
Coherus Biosciences USD 140.39M 231.91M 2025-12
Eli Lilly USD 35.23B 4.91B 2025-12
Gilead Sciences USD 11.81B 485M 2025-12
Heron Therapeutics USD 96.1M 6.39M 2025-12
Ionis Pharmaceuticals USD 783M 120.46M 2025-12
J&J USD 54.13B 3.26B 2025-12
Malin Corporation EUR 1000K 500K 2024-12
Merck USD 28.63B 2.59B 2025-09
Minerva Neurosciences USD 2.29M 381K 2025-12
Nektar Therapeutics USD 53.54M 12.8M 2025-12
Neurocrine Biosciences USD 743.4M 105.4M 2025-12
Otsuka Holdings JPY 749.11B 50.84B 2025-12
Ovoca Bio EUR 186K 2.26M 2025-06
Pfizer USD 36.6B 1.13B 2025-09
Regeneron Pharmaceuticals USD 4.37B 56.7M 2025-12
Vertex Pharmaceuticals USD 3.86B 614.1M 2025-12